Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II 12/10/2023 – 11/10/2024
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F24%3A00138349" target="_blank" >RIV/00216224:14110/24:00138349 - isvavai.cz</a>
Result on the web
<a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002936-55" target="_blank" >https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002936-55</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II 12/10/2023 – 11/10/2024
Original language description
The second periodic safety report for the „Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II“ (acronym MSC-EB) evaluates the safety data received by the sponsor (Masaryk University Brno) during the period 12/10/2023 to 11/10/2024. The CT is performed in 2 centers in the Czech Republic
Czech name
—
Czech description
—
Classification
Type
V<sub>souhrn</sub> - Summary research report
CEP classification
—
OECD FORD branch
30230 - Other clinical medicine subjects
Result continuities
Project
—
Continuities
—
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Number of pages
28
Place of publication
Brno
Publisher/client name
MU LF/MŠMT/FN BRNO
Version
—